Business
Spectral to Present at Investor Summit Group's Q2 In-person Conference on May 3rd in NYC
Toronto, Ontario--(Newsfile Corp. - April 27, 2022) - Spectral Medical Inc.  (TSX: EDT)...
About this update from Spectral Medical Inc
[{"type":"text","content":"Spectral to Present at Investor Summit Group's Q2 In-person Conference on May 3rd in NYCToronto, Ontario--(Newsfile Corp. - April 27, 2022) - Spectral Medical Inc. (TSX: EDT) (\"Spectral\" or the \"Company\"), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (\"Dialco\"), today announced that Chris Seto, CEO and Dr. Jon Kellum, CMO of Spectral Medical will be presenting at The Q2 Investor Summit, hosted by the Investor Summit Group, being held on May 3-4, 2022 at The Westin New York Grand Central. Event: The Q2 Investor Summit Group Date: May 3-4, 2022 Location:The Westin New York Grand Central 212 E 42nd St, New York, NY 10017 Presentation: May 3rd at 2:45 PM ET Webcast: https://us06web.zoom.us/webinar/register/WN_jnFz6BeqQgWBQKQXZEInXg Management will also host 1x1 meetings with investors throughout the conference. 1x1 meetings will be available for qualified investors. The conference is completely complimentary to qualified investors. Please register at Complimentary Investor Registration.About the Investor Summit GroupThe Investor Summit Group (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q2 Investor Summit Group will take place in-person, featuring 65+ companies and over 300 investors comprising institutional investors, family offices, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Energy/Tech, Financial, Healthcare, Industrials, Materials, Real Estate, Technology, and Tech/Crypt. [email protected] SpectralSpectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (\"PMX\"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.PMX is approved for therapeutic use in Japan and Europe, and has been used...